Analysts Are Bullish on These Healthcare Stocks: HSDT, QTNT


There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Helius Medical Technologies (NASDAQ: HSDT), Quotient Ltd (NASDAQ: QTNT) and Voyager Therapeutics Inc (NASDAQ: VYGR) with bullish sentiments.

Helius Medical Technologies (NASDAQ: HSDT)

In a report issued on May 17, Sean Lavin from BTIG assigned a Buy rating to Helius Medical Technologies (NASDAQ: HSDT), with a price target of $14. The company’s shares opened today at $11.02.

Lavin wrote:

“Against Imperfect Data; Initiating w/a Buy and $14 PT Helius has the potential to help people with traumatic brain injuries to regain normal function, balance, and the ability to walk.”

According to TipRanks.com, Lavin is a 5-star analyst with an average return of 15.0% and a 63.0% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Obalon Therapeutics Inc, and Boston Scientific Corp.

Helius Medical Technologies has an analyst consensus of Hold.

See today’s analyst top recommended stocks >>

Quotient Ltd (NASDAQ: QTNT)

BTIG analyst Sung Ji Nam assigned a Buy rating to Quotient Ltd (NASDAQ: QTNT) on May 18 and set a price target of $10. The company’s shares opened today at $6.15.

Ji Nam observed:

“Much Awaited EU Blood Grouping (IH Another step closer to the commercial launch of potentially revolutionary platform in the $3bn transfusion diagnostics market: Yesterday after the close, QTNT announced that it has commenced its European field trials for its initial blood grouping MosaiQ microarray (IH I). This follows the successful completion of the internal verification and validation (V&V) studies (previously announced), and the preparation and training of the field trial sites. The field trials will be performed across three sites and entail ~3,000 donor samples, and the concordance data (“head- to-head”) is expected to be published in June. Importantly, from a capital availability standpoint, the $36mm in debt facility becomes accessible with the successful completion of the head-to-head study component of the field trials.”

According to TipRanks.com, Nam is a 3-star analyst with an average return of 3.4% and a 74.7% success rate. Nam covers the Healthcare sector, focusing on stocks such as Oxford Immunotec, Myriad Genetics, and Thermo Fisher.

Quotient Ltd has an analyst consensus of Moderate Buy, with a price target consensus of $10.

Voyager Therapeutics Inc (NASDAQ: VYGR)

In a report released today, Dane Leone from BTIG reiterated a Buy rating on Voyager Therapeutics Inc (NASDAQ: VYGR), with a price target of $32. The company’s shares opened today at $19.08.

Leone wrote:

“Huntington’s and ALS Voyager hosted their Breakfast event at the ASGCT Annual Meeting in Chicago. At the event, management confirmed that the first pivotal study for their lead program in Parkinson’s Disease remains on track to begin in mid-summer of 2018. Mgmt also provided data updates on their very promising early-stage pipeline programs, and reaffirmed their commitment to pursue at least two IND submissions during 2019. We reiterate our Buy rating and $32 PT.”

According to TipRanks.com, Leone is a 5-star analyst with an average return of 21.1% and a 70.6% success rate. Leone covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Blueprint Medicines, and G1 Therapeutics Inc.

Currently, the analyst consensus on Voyager Therapeutics Inc is Strong Buy and the average price target is $35.50, representing an 86.1% upside.

In a report issued on May 10, Cowen & Co. also maintained a Buy rating on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts